Skip to main content
SpringerLink
Log in

Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

Tumor necrosis factor (TNF) induces cancer cell-specific apoptosis by binding to a TNF-related apoptosis-inducing ligand. Binding of the Fas ligand on cytotoxic T lymphocytes to the Fas receptor on hepatocytes is also known to induce apoptosis. The aim of this study was to clarify changes of cytokines in patients with liver cirrhosis (LC) and advanced hepatocellular carcinoma (aHCC) receiving intra-arterial combination chemotherapy.

Methods

Twenty-one adult Japanese LC patients with aHCC received intra-arterial combination chemotherapy. The serum levels of TNF-alpha, soluble TNF receptor-I (sTNFr-I), soluble Fas ligand (sFas L), and soluble Fas (sFas) were evaluated.

Results

Thirteen of the 21 patients (group R) showed an objective response, while the other eight patients (group N) showed no response. The serum level of TNF-alpha was lower after chemotherapy than before chemotherapy in group N, but there was no difference of serum sTNFr-I levels between before and after chemotherapy and there were also no differences between the two groups. The serum sFas levels were higher after chemotherapy than before chemotherapy in group N, while there was no difference among groups.

Conclusions

These results indicate that a high serum TNF-alpha level and a low serum sFas level might be important for successful combined arterial chemotherapy in LC patients with aHCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Onishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918–928

    Article  PubMed  CAS  Google Scholar 

  2. Nagasue N, Yukaya H, Hamada T, Hirosue S, Kanashima R, Inokuchi K (1984) The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer 54:1461–1465

    Article  PubMed  CAS  Google Scholar 

  3. Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, Kirishima S, Suga T, Takahashi M (1995) The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 52:295–299

    Article  PubMed  CAS  Google Scholar 

  4. Murata K, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Sakai Takahisa, Deguchi M, Ohmori S, Nakano T (2003) Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted fusion port for unresectable hepatocellular carcinoma. Anticancer Res 23:1719–1722

    PubMed  CAS  Google Scholar 

  5. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Takikawa K (1999) Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 6:587–591

    PubMed  CAS  Google Scholar 

  6. Nagai H, Matsui T, Kanayama M, Momiyama K, Ikoma A, Okano N, Ikehara T, Matsumaru K, Watanabe M, Iida K, Ishii K, Sumino Y, Miki K (2007) Assessment of combined intra-arterial low-dose 5-fluorouracil, cisplatin, and leucovolin chemotherapy for patients with advanced hepatocellular carcinoma using the Japan integrated staging score. J Med Soc Toho 54:21–28

    Google Scholar 

  7. Nagai H, Kanayama M, Higami K, Momiyama K, Ikoma A, Okano N, Matsumaru K, Watanabe M, Ishii K, Sumino Y, Miki K (2007) Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. World J Gastroenterol 13(2):280–284

    PubMed  CAS  Google Scholar 

  8. Scanlon KJ, Newman EW, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923–8925

    Article  PubMed  CAS  Google Scholar 

  9. Shirasaka T, Shimamoto Y, Ohsimo H, Saito M, Fukusima M (1993) Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32:167–172

    Article  PubMed  CAS  Google Scholar 

  10. Ensminger WD, Gyves JW (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10:176–182

    PubMed  CAS  Google Scholar 

  11. Shiraki K, Yamanaka T, Inoue H, Kawakita T, Enokimura N, Okano Hiroshi, Sugimoto K, Murata K, Nakano T (2005) Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol 26:1273–1281

    PubMed  CAS  Google Scholar 

  12. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ (2000) Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60:847–853

    PubMed  CAS  Google Scholar 

  13. Wenn J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96:3900–3906

    Google Scholar 

  14. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11:S86–S96

    Article  PubMed  CAS  Google Scholar 

  15. Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, Damdinsuren B, Ota H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Yagita H, Monden M (2004) Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of onterferon-alpha/5-fluorouracil against hepatocellular carcinoma. Clin Cancer Res 10:7884–7895

    Article  PubMed  CAS  Google Scholar 

  16. Nagata S, Golstein P (1995) The Fas death factor. Science 267:1449–1455

    Article  PubMed  CAS  Google Scholar 

  17. Armitage RJ (1994) Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6:407–413

    Article  PubMed  CAS  Google Scholar 

  18. Nakamura M, Nagano H, Sakon M, Yamamoto T, Ota H, Wada H, Damdisuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Dono K, Monden M (2007) Role of the Fas/FasL pathway in combination therapy with interferon-a and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 46:77–88

    Article  PubMed  CAS  Google Scholar 

  19. Iwamiya T, Sawada S, Ohta Y (1994) Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system. Cancer Chemother Pharmacol 33(Suppl):S134–S138

    Article  PubMed  Google Scholar 

  20. Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for new staging system, the Japan integrated staging score (JIS score). J Gastroenterol 38:207–215

    Article  PubMed  Google Scholar 

  21. Beutler B, Cerami A (1998) Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response. Endocr Rev 9:57–66

    Article  Google Scholar 

  22. Tracey KJ, Vlassara H, Cerami A (1989) Cachectin/tumor necrosis factor. Lancet 1(8647):1122–1126

    Article  PubMed  CAS  Google Scholar 

  23. Brockhause M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H (1990) Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci USA 87:3127–3131

    Article  Google Scholar 

  24. Hohmann HP, Remy R, Brockhause M, Van Loon AP (1989) Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 264:1429–1434

    Google Scholar 

  25. Ruberti G, Cascino I, Papoff G, Eramo A (1996) Fas splicing variants and their effect on apoptosis. Adv Exp Med Biol 406:125–134

    PubMed  CAS  Google Scholar 

  26. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Hiramatsu N, Kanto T, Sasaki Y, Kasahara A, Hori M (1998) Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 29:517–523

    Article  PubMed  CAS  Google Scholar 

  27. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, Bach JF, Brechot C, Zavala F (1999) Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30:185–191

    Article  PubMed  CAS  Google Scholar 

  28. Waage A, Liabakk N, Lien E, Lamvik J, Espevik T (1992) p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood 80:2577–2583

    PubMed  CAS  Google Scholar 

  29. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, Portmann B, Williams R (1995) Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 108:1453–1463

    Article  PubMed  CAS  Google Scholar 

  30. Seishima M, Takemura M, Saito K, Ando K, Noma A (1997) Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol 27:424–425

    Article  PubMed  CAS  Google Scholar 

  31. Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T (1998) Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 112:166–1671

    Article  PubMed  CAS  Google Scholar 

  32. Hayashi N, Mita E (1997) Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol 12:S223–S226

    Article  PubMed  CAS  Google Scholar 

  33. Peng Z, Tang H, Ling Y, Han G (2001) Apoptosis and Fas system are significantly involved in the process of liver cirrhosis converting into HCC. J Tongji Med Univ 21(2):126–129

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Toho University Medical Center, Omori Hospital, 6-11-1, Omorinishi, Ota-ku, Tokyo, 143-8541, Japan

    Hidenari Nagai, Daisuke Miyaki, Teppei Matsui, Masahiro Kanayama, Katsuya Higami, Kouichi Momiyama, Takashi Ikehara, Manabu Watanabe, Yasukiyo Sumino & Kazumasa Miki

Authors
  1. Hidenari Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daisuke Miyaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teppei Matsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiro Kanayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Katsuya Higami
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kouichi Momiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takashi Ikehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Manabu Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasukiyo Sumino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazumasa Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hidenari Nagai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagai, H., Miyaki, D., Matsui, T. et al. Changes of cytokines in cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy. Cancer Chemother Pharmacol 62, 271–276 (2008). https://doi.org/10.1007/s00280-007-0602-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0602-9

Keywords

Search

Navigation